Pooled Analysis of Four RCTs on PD-1/PD-L1 Inhibitors Plus Anti-VEGF Drugs for HCC

A pooled analysis of four randomized controlled trials (CARES-005, EMERALD-1, LEAP-012, TALENTACE) involving 1,431 patients with unresectable, non-metastatic hepatocellular carcinoma. The dataset, authored by Tonggang Zhou and last updated in May 2026, compares the combination of PD-1/PD-L1 inhibitors and anti-VEGF drugs after TACE versus TACE alone, analyzing endpoints like overall survival, progression-free survival, tumor response, and adverse events.

Use Cases

• Compare progression-free survival and overall survival outcomes between combination therapy and TACE alone based on hazard ratios.
• Analyze the incidence and severity of treatment-related adverse events based on grade 3–4/serious adverse event data.
• Evaluate tumor response rates using objective response rate metrics based on RECIST and mRECIST criteria.
• Perform subgroup analyses to assess treatment benefit consistency across different patient populations.

Strengths

• Includes data from four randomized controlled trials (CARES-005, EMERALD-1, LEAP-012, TALENTACE), a standard for clinical evidence.
• Analyzes 1,431 patient records, providing a substantial sample size for pooled analysis.
• Assesses multiple endpoints including survival, tumor response, and adverse events, offering a multi-faceted view of treatment impact.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• The dataset is a 23.8 KB DOCX file, suggesting limited scope and likely summary tables rather than raw patient-level data.

Provenance

Source

figshare, authored by Tonggang Zhou.

Collection Method

Pooled analysis of RCTs identified via systematic search of six databases.

Freshness

Last updated 2026-05-25 13:05:30; freshness should be verified.